Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo.
Tsumagari K, Abd Elmageed ZY, Sholl AB, Green EA, Sobti S, Khan AR, Kandil A, Murad F, Friedlander P, Boulares AH, Kandil E.
Tsumagari K, et al. Among authors: murad f.
Endocr Relat Cancer. 2018 Jan;25(1):99-109. doi: 10.1530/ERC-17-0182.
Endocr Relat Cancer. 2018.
PMID: 29269566
Free PMC article.